respiratory
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
The Autumn 2020 edition of Pharmafile is available to read for free online now!
December 1, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing infectious diseases, pharmafile, rare disease, respiratory
The Autumn 2020 edition of Pharmafile is available to read for free online now! 2020 has seen almost unprecedented disruption …
Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement
April 9, 2020Sales and Marketing AstraZeneca, Circassia, partnership, pharma, respiratory
Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with AstraZeneca UK back in 2017 …
AZ’s first respiratory biologic meets primary endpoints in Phase III trials
September 5, 2016Research and Development, Sales and Marketing AstraZeneca, asthma, benralizumab, biologic, respiratory, severe asthma
AstraZeneca has presented Phase III data at the European Respiratory Society (ERS) international congress which shows that trial biologic benralizumab …
GlaxoSmithKline opens new £56 million facility in Hertfordshire
April 19, 2016Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware
GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England. The facility in Ware will create 150 …
AstraZeneca to acquire Takeda’s respiratory franchise
December 16, 2015Manufacturing and Production, Research and Development AstraZeneca, China, Takeda, investment, respiratory
AstraZeneca and Takeda have agreed a multi-million pound deal for AZ to acquire the Japanese firm’s core respiratory business, including …
Generics continue to erode GSK sales
May 6, 2015Sales and Marketing GSK, HIV, Novartis, Q1, ViiV, Witty, hampton, respiratory
GlaxoSmithKline’s pharma sales continued to slide in the first quarter of 2015, but ViiV healthcare and the portfolios acquired from …
AstraZeneca buoyed by late-stage trial success
March 18, 2015Sales and Marketing AstraZeneca, copd. asthma, formoterol fumarate, glycopyrronium, ptoo3, respiratory
AstraZeneca’s investigational respiratory drug has posted positive results in a Phase III trial in people with COPD, having found it …
AstraZeneca completes respiratory deal with Actavis
March 3, 2015Research and Development, Sales and Marketing Actavis, AstraZeneca, COPD, Daliresp, Tudorza Pressair, aclidinium bromide inhalation powder, respiratory, roflumilast
AstraZeneca has completed its acquisition of Dublin-headquartered firm Actavis with its branded respiratory portfolio deal worth $700 million. The agreement …
Takeda acquires Turkish firm Neutec
February 24, 2015Sales and Marketing Takeda, Turkey, gastroenterology, neutec, respiratory, turkish
Takeda has signed an agreement to acquire one of Turkey’s leading pharma firms Neutec in a $120 million deal. The …
AstraZeneca loses US Pulmicort patent
February 16, 2015Sales and Marketing AstraZeneca, Budesonide Inhalation Suspension, asthma, pulmicourt, respiratory
British drugmaker AstraZeneca has been dealt a blow by the courts in the US, after a district judge ruled its …
GSK confirms hundreds of US job cuts
December 3, 2014Medical Communications, Research and Development, Sales and Marketing Advair, GSK, Parexel, RTP, anoro, breo, job cuts, respiratory
GlaxoSmithKline has finally confirmed the rumours that it is cutting hundreds of US jobs as the UK firm struggles to …
AstraZeneca completes respiratory deal with Almirall
November 3, 2014Research and Development, Sales and Marketing Almirall, AstraZeneca, Pfizer, deal, duaklir, merger, respiratory
AstraZeneca has finally completed its takeover of Almirall’s respiratory drug portfolio in a deal worth $875 million. As reported by …
Novartis emphasises pharma growth
June 19, 2014Sales and Marketing Novartis, breezhaler, dermatology, heart failure, oncology, respiratory
Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …
AstraZeneca signs respiratory deal
January 29, 2013Research and Development, Sales and Marketing AstraZeneca, COPD, orexo, respiratory
AstraZeneca has signed a research deal with Swedish pharma company Orexo centred around the development of respiratory disease treatments. For …
